Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mafenide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 18/20 | 0.91 |
| ▸ | CA1 | P00915 | 12/20 | 0.91 |
| ▸ | CA12 | O43570 | 10/20 | 0.91 |
| ▸ | CA9 | Q16790 | 10/20 | 0.91 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.91 |
| ▸ | CA4 | P22748 | 5/20 | 0.91 |
| ▸ | CA6 | P23280 | 5/20 | 0.91 |
| ▸ | CA5A | P35218 | 5/20 | 0.91 |
| ▸ | CA7 | P43166 | 5/20 | 0.91 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.91 |
| ▸ | MAPT | P10636 | 1/20 | 0.87 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mafenide SCHEMBL27294054 | 0.98 | CA2 (0.87) | CA2CA1CA12CA9CA14 | |
| Mafenide SCHEMBL9295695 | 0.95 | CA2 (1.00) | CA2CA1CA12CA9CA14 | |
| Mafenide SCHEMBL41628 | 0.95 | CA2 (1.00) | CA2CA1CA12CA9CA14 | |
| Mafenide SCHEMBL1203324 | 0.93 | CA2 (1.00) | CA2CA1CA12CA9CA14 | |
| Mafenide SCHEMBL425524 | 0.93 | CA2 (1.00) | CA2CA1CA12CA9CA14 | |
| Mafenide SCHEMBL686407 | 0.91 | CA2 (0.95) | CA2CA1CA12CA9CA14 | |
| Mafenide SCHEMBL1072130 | 0.89 | CA2 (0.87) | CA2CA1CA12CA9CA14 | |
| Mafenide SCHEMBL11664949 | 0.87 | CA2 (0.83) | CA2CA1CA12CA9CA14 | |
| Mafenide SCHEMBL27599824 | 0.85 | KDM4E (0.82) | CA2CA1CA12CA9CA14 | |
| Mafenide SCHEMBL28285713 | 0.85 | CA2 (0.71) | CA2CA1CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773791-B1 | PYRROLOTRIAZINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2010-09-22 | — | — | EP | disclosed |
| EP-1773791-A4 | PYRROLOTRIAZINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-1773791-A1 | PYRROLOTRIAZINE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2007-04-18 | — | — | EP | disclosed |
| US-7102003-B2 | Pyrrolotriazine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| WO-2006007468-A1 | PYRROLOTRIAZINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-19 | — | — | WO | disclosed |
| US-20060014745-A1 | Pyrrolotriazine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-19 | — | — | US | disclosed |
| CN-1041920-C | Glycerin derivative and its pharmacological use | EISAI CO LTD (JP) | 1999-02-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014745-A1 | Pyrrolotriazine compounds | ERBB2, ERBB4, EGFR | CA2 1744/4885CA1 3474/4885CA12 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.